journal article·2022-09Open access

The E3 Ligase TRIM4 Facilitates SET Ubiquitin‐Mediated Degradation to Enhance ER‐α Action in Breast Cancer

Dianwen Han, Lijuan Wang, Li Long, Peng Su, Dan Luo, Hanwen Zhang, Zheng Li, Bing Chen, Wenjing Zhao, Ning Zhang, Xiaolong Wang, Yiran Liang, Yaming Li, Guohong Hu, Qifeng Yang

Advanced Science· Volume 9· Issue 25

Abstract

Abstract Estrogen receptor alpha (ER‐α) action is critical for hormone‐dependent breast cancer, and ER‐α dysregulation can lead to the emergence of resistance to endocrine therapy. Here, it is found that TRIM4 is downregulated in tamoxifen (TAM)‐resistant breast cancer cells, while the loss of TRIM4 is associated with an unfavorable prognosis. In vitro and in vivo experiments confirm that TRIM4 increased ER‐α expression and the sensitivity of breast cancer cells to TAM. Mechanistically, TRIM4 is found to target SET, and TRIM4‐SET interactions are mediated by the RING and B‐box domains of TRIM4 and the carboxyl terminus of SET. Moreover, it is determined that TRIM4 catalyzed the K48‐linked polyubiquitination of SET (K150 and K172), promoting its proteasomal degradation and disassociation from p53 and PP2A. Once released, p53 and PP2A are able to further promote ESR1 gene transcription and enhance mRNA stability. Moreover, univariate and multivariate Cox proportional hazards regression analyses confirm that TRIM4 expression is an independent predictor of overall survival and recurrence‐free survival outcomes in patients with ER‐α positive breast cancer. Taken together, the data highlights a previously undiscovered mechanism and suggest that TRIM4 is a valuable biomarker that can be analyzed to predict response to endocrine therapy in breast cancer patients.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ubiquitin and proteasome pathways · interferon and immune responses · Protein Degradation and Inhibitors

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Breast Surgery, General Surgery Qilu Hospital of Shandong University Jinan Shandong 250012 China

Pathology Tissue Bank Qilu Hospital of Shandong University Jinan Shandong 250012 China

Mianyang Central Hospital School of Medicine University of Electronic Science and Technology of China Mianyang Sichuan 621000 China

Department of Pathology Qilu Hospital of Shandong University Jinan Shandong 250012 China

The Key Laboratory of Stem Cell Biology Institute of Health Sciences Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine University of Chinese Academy of Sciences Shanghai 200233 China

Research Institute of Breast Cancer Shandong University Jinan Shandong 250012 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · China Postdoctoral Science Foundation · Key Technology Research and Development Program of Shandong

References (85)

Show source-provided references
1. 10.1016/j.semcancer.2019.08.01210.1016/j.semcancer.2019.08.012 ↗
2. 10.1016/S0140-6736(20)32381-310.1016/S0140-6736(20)32381-3 ↗
3. 10.1093/jnci/dju05510.1093/jnci/dju055 ↗
4. 10.1038/s41467-020-20814-910.1038/s41467-020-20814-9 ↗
5. 10.15252/emmm.20191063810.15252/emmm.201910638 ↗
6. 10.1038/s41467-020-18129-w10.1038/s41467-020-18129-w ↗
7. 10.1186/s13058-020-01296-510.1186/s13058-020-01296-5 ↗
8. 10.1172/JCI7374310.1172/JCI73743 ↗
9. 10.1158/0008-5472.CAN-08-362810.1158/0008-5472.CAN-08-3628 ↗
10. 10.1007/s12253-011-9423-610.1007/s12253-011-9423-6 ↗
11. 10.1074/jbc.M50531720010.1074/jbc.M505317200 ↗
12. 10.3390/jcm709024510.3390/jcm7090245 ↗
13. 10.1073/pnas.131763011110.1073/pnas.1317630111 ↗
14. 10.1016/j.bbrc.2014.09.01310.1016/j.bbrc.2014.09.013 ↗
15. 10.1038/nature1975910.1038/nature19759 ↗
16. 10.1042/bj341029310.1042/bj3410293 ↗
17. 10.1006/bbrc.1999.079010.1006/bbrc.1999.0790 ↗
18. 10.1038/sj.onc.120707710.1038/sj.onc.1207077 ↗
19. 10.1681/ASN.V910187310.1681/ASN.V9101873 ↗
20. 10.1371/journal.pone.005343610.1371/journal.pone.0053436 ↗
21. 10.1158/0008-5472.CAN-04-456410.1158/0008-5472.CAN-04-4564 ↗
22. 10.1158/1078-0432.CCR-14-072410.1158/1078-0432.CCR-14-0724 ↗
23. 10.18632/oncotarget.381810.18632/oncotarget.3818 ↗
24. 10.1038/onc.2016.2110.1038/onc.2016.21 ↗
25. 10.1186/1476-4598-13-3210.1186/1476-4598-13-32 ↗
26. 10.1016/j.pharmthera.2021.10788110.1016/j.pharmthera.2021.107881 ↗
27. 10.1016/j.tibs.2017.01.00210.1016/j.tibs.2017.01.002 ↗
28. 10.1038/s41418-020-0495-210.1038/s41418-020-0495-2 ↗
29. 10.1093/jmcb/mju00510.1093/jmcb/mju005 ↗
30. 10.1016/j.freeradbiomed.2015.10.42510.1016/j.freeradbiomed.2015.10.425 ↗
31. 10.7150/jca.3716410.7150/jca.37164 ↗
32. 10.1186/s43556-021-00045-010.1186/s43556-021-00045-0 ↗
33. 10.3892/ijo.2015.287810.3892/ijo.2015.2878 ↗
34. 10.1242/jcs.25650310.1242/jcs.256503 ↗
35. 10.1016/j.canlet.2016.11.00410.1016/j.canlet.2016.11.004 ↗
36. 10.1002/jcp.2962910.1002/jcp.29629 ↗
37. 10.1073/pnas.060376210410.1073/pnas.0603762104 ↗
38. 10.1126/sciadv.abe587710.1126/sciadv.abe5877 ↗
39. 10.1038/s41418-020-0568-210.1038/s41418-020-0568-2 ↗
40. 10.3389/fphar.2020.59291210.3389/fphar.2020.592912 ↗
41. 10.1016/j.ccell.2020.03.00910.1016/j.ccell.2020.03.009 ↗
42. 10.1093/nar/27.3.90310.1093/nar/27.3.903 ↗
43. Turner B. C. · Cancer Res. · 1998 · 58 · 5466
44. 10.1186/bcr187210.1186/bcr1872 ↗
45. 10.1038/onc.2010.4710.1038/onc.2010.47 ↗
46. 10.1016/j.ceb.2008.02.00310.1016/j.ceb.2008.02.003 ↗
47. 10.1677/joe.0.180049710.1677/joe.0.1800497 ↗
48. 10.1074/jbc.M70474520010.1074/jbc.M704745200 ↗
49. 10.1007/s10549-007-9751-010.1007/s10549-007-9751-0 ↗
50. 10.1074/jbc.M21094920010.1074/jbc.M210949200 ↗
51. 10.1371/journal.pone.001540810.1371/journal.pone.0015408 ↗
52. 10.1210/me.15.8.134410.1210/me.15.8.1344 ↗
53. 10.1158/0008-5472.CAN-05-436310.1158/0008-5472.CAN-05-4363 ↗
54. 10.1158/1078-0432.CCR-07-058710.1158/1078-0432.CCR-07-0587 ↗
55. 10.1146/annurev-med-070909-18291710.1146/annurev-med-070909-182917 ↗
56. 10.1016/j.celrep.2020.10793110.1016/j.celrep.2020.107931 ↗
57. 10.1038/sj.leu.240382610.1038/sj.leu.2403826 ↗
58. 10.1146/annurev.biochem.67.1.42510.1146/annurev.biochem.67.1.425 ↗
59. 10.1016/bs.ai.2019.11.00410.1016/bs.ai.2019.11.004 ↗
60. 10.1038/nrm339410.1038/nrm3394 ↗
61. 10.1038/nsmb0108-2010.1038/nsmb0108-20 ↗
62. 10.1016/j.bbamcr.2004.09.01910.1016/j.bbamcr.2004.09.019 ↗
63. 10.1016/j.molcel.2009.01.01410.1016/j.molcel.2009.01.014 ↗
64. Tian Z. · Am. J. Cancer Res. · 2020 · 10 · 3440
65. 10.1158/0008-5472.CAN-07-096710.1158/0008-5472.CAN-07-0967 ↗
66. 10.1210/me.2005-011110.1210/me.2005-0111 ↗
67. 10.1210/me.2009-021810.1210/me.2009-0218 ↗
68. 10.1038/onc.2013.57310.1038/onc.2013.573 ↗
69. 10.1038/s41388-021-02038-310.1038/s41388-021-02038-3 ↗
70. 10.1073/pnas.210078411810.1073/pnas.2100784118 ↗
71. 10.1016/j.omtn.2020.10.01210.1016/j.omtn.2020.10.012 ↗
72. 10.1007/s10549-020-05899-610.1007/s10549-020-05899-6 ↗
73. 10.1038/sj.emboj.760151810.1038/sj.emboj.7601518 ↗
74. 10.1002/(SICI)1097-4644(19990701)74:1<119::AID-JCB13>3.0.CO;2-710.1002/(SICI)1097-4644(19990701)74:1<119::AID-JCB13>3.0.CO;2-7 ↗
75. 10.1074/jbc.M20749720010.1074/jbc.M207497200 ↗
76. 10.1186/1471-2202-15-8210.1186/1471-2202-15-82 ↗
77. 10.1089/10445490175334060410.1089/104454901753340604 ↗
78. 10.1016/j.cca.2016.11.01010.1016/j.cca.2016.11.010 ↗
79. 10.1007/s00401-011-0908-x10.1007/s00401-011-0908-x ↗
80. 10.1158/1078-0432.CCR-13-257510.1158/1078-0432.CCR-13-2575 ↗
81. 10.1038/s41408-019-0270-010.1038/s41408-019-0270-0 ↗
82. 10.1182/blood-2011-04-35107210.1182/blood-2011-04-351072 ↗
83. 10.1111/bjh.1567710.1111/bjh.15677 ↗
84. 10.1038/s41598-017-07550-910.1038/s41598-017-07550-9 ↗
85. 10.1093/ecco-jcc/jjab08610.1093/ecco-jcc/jjab086 ↗